SG10201806729VA - Novel assay to detect human periostin - Google Patents

Novel assay to detect human periostin

Info

Publication number
SG10201806729VA
SG10201806729VA SG10201806729VA SG10201806729VA SG10201806729VA SG 10201806729V A SG10201806729V A SG 10201806729VA SG 10201806729V A SG10201806729V A SG 10201806729VA SG 10201806729V A SG10201806729V A SG 10201806729VA SG 10201806729V A SG10201806729V A SG 10201806729VA
Authority
SG
Singapore
Prior art keywords
periostin
detect human
human periostin
novel assay
assay
Prior art date
Application number
SG10201806729VA
Other languages
English (en)
Inventor
Partha Chowdhury
Reena Varkey
Meina Liang
Yen-Wah Lee
Katie Streicher
Koustubh Ranade
Ethan Grant
Lydia Greenlees
Yihong Yao
Melissa Parker
Gerard Davis
Nicolette Jeanblanc
Susan Brophy
Bruce Dille
Original Assignee
Medimmune Llc
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Abbott Lab filed Critical Medimmune Llc
Publication of SG10201806729VA publication Critical patent/SG10201806729VA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
SG10201806729VA 2014-02-07 2015-02-05 Novel assay to detect human periostin SG10201806729VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461936967P 2014-02-07 2014-02-07

Publications (1)

Publication Number Publication Date
SG10201806729VA true SG10201806729VA (en) 2018-09-27

Family

ID=52574429

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201806729VA SG10201806729VA (en) 2014-02-07 2015-02-05 Novel assay to detect human periostin
SG11201606322XA SG11201606322XA (en) 2014-02-07 2015-02-05 Novel assay to detect human periostin

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201606322XA SG11201606322XA (en) 2014-02-07 2015-02-05 Novel assay to detect human periostin

Country Status (14)

Country Link
US (3) US10775388B2 (enExample)
EP (2) EP3102951A1 (enExample)
JP (3) JP6549132B2 (enExample)
KR (2) KR20160122756A (enExample)
CN (2) CN106170497A (enExample)
AU (2) AU2015214103A1 (enExample)
BR (2) BR112016017926A2 (enExample)
CA (2) CA2936285A1 (enExample)
HK (2) HK1232290A1 (enExample)
MX (2) MX2016009450A (enExample)
RU (2) RU2016135417A (enExample)
SG (2) SG10201806729VA (enExample)
TW (1) TW201542589A (enExample)
WO (2) WO2015120185A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1255922A1 (zh) 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子
WO2018030456A1 (ja) * 2016-08-10 2018-02-15 株式会社シノテスト 試料に含まれるペリオスチンの測定試薬、ペリオスチン測定用前処理剤、ペリオスチン測定方法及びペリオスチン測定の感度の改善方法
WO2018194134A1 (ja) * 2017-04-20 2018-10-25 株式会社シノテスト 抗ペリオスチン抗体固定化担体、ペリオスチン測定試薬、及び抗ペリオスチン抗体固定化担体における抗体の安定化方法
US12281171B2 (en) 2018-03-19 2025-04-22 Bio Ventures, Llc Periostin antibodies and methods of using the same
CN109879963A (zh) * 2019-03-15 2019-06-14 辽宁何氏医学院 一种抑制组织器官纤维化和新生血管形成的单克隆抗体及其制备方法和应用
EP3959221A4 (en) 2019-04-26 2024-01-10 Cornell University KLEBSIELLA VACCINE AND METHODS OF USE
US20250035618A1 (en) * 2021-12-28 2025-01-30 Sekisui Medical Co., Ltd. Detection method and detection reagent
CN115078734A (zh) * 2022-06-15 2022-09-20 苏州方达新药开发有限公司 一种细胞因子融合蛋白的检测分析方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
ES2599532T3 (es) 2005-05-30 2017-02-02 Organ Technologies Inc. Método para producir un diente, conjunto de dientes, y método para producir un tejido
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
CA2635849C (en) * 2005-12-28 2017-05-09 Asubio Pharma Co., Ltd. An antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
KR101560843B1 (ko) 2007-06-27 2015-10-15 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
EP2271770B1 (en) 2008-03-31 2018-08-22 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
EP2274010A1 (en) 2008-04-11 2011-01-19 Biogen Idec MA Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds
FR2946349B1 (fr) 2009-06-03 2013-10-04 Synarc Sas Sequences, anticorps, procedes et necessaires pour la detection et le dosage in vitro de la periostine, en vue du diagnostic du suivi ou du pronostic de pathologies ou de phenomenes biologiques impliquant la periostine
WO2012083132A2 (en) * 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
WO2012156513A1 (en) 2011-05-18 2012-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for determining whether a subject is at risk of having or developing a chronic kidney disease
WO2013035799A1 (ja) 2011-09-06 2013-03-14 株式会社シノテスト ペリオスチンの特定領域に結合する抗体及びこれを用いたペリオスチンの測定方法
JP5797148B2 (ja) 2011-09-12 2015-10-21 富士フイルム株式会社 コレステリック液晶性混合物、フィルム、選択反射板、積層体および合わせガラス
WO2013038696A1 (ja) * 2011-09-15 2013-03-21 国立大学法人名古屋大学 胸膜中皮腫患者の早期発見のための分子マーカー及びその発現解析方法
AU2013222129B2 (en) 2012-02-24 2018-02-15 Children's Hospital Medical Center Esophageal microRNA expression profiles in eosinophilic esophagitis
EP2875049B1 (en) * 2012-07-18 2018-12-26 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for preventing and treating chronic kidney disease (ckd)
AU2015209124A1 (en) * 2014-01-27 2016-08-18 Medimmune, Llc Dipeptidyl peptidase-4 (DPP4/CD26) as a peripheral biomarker of IL-13 activation in asthmatic lung

Also Published As

Publication number Publication date
CN106164675A (zh) 2016-11-23
JP2017506064A (ja) 2017-03-02
CN106170497A (zh) 2016-11-30
RU2016135418A3 (enExample) 2018-10-30
HK1232238A1 (zh) 2018-01-05
JP2020000236A (ja) 2020-01-09
RU2016135417A3 (enExample) 2018-10-31
MX2016009490A (es) 2017-05-12
US10775388B2 (en) 2020-09-15
CA2936285A1 (en) 2015-08-13
EP3102601B1 (en) 2020-09-02
CN106164675B (zh) 2019-04-23
JP2017507322A (ja) 2017-03-16
CA2936258A1 (en) 2015-08-13
HK1232290A1 (zh) 2018-01-05
BR112016017901A2 (pt) 2017-10-10
RU2016135418A (ru) 2018-03-13
MX2016009450A (es) 2017-04-27
AU2015214089A1 (en) 2016-07-21
KR20160122756A (ko) 2016-10-24
TW201542589A (zh) 2015-11-16
EP3102601A1 (en) 2016-12-14
WO2015120185A1 (en) 2015-08-13
KR20160125409A (ko) 2016-10-31
WO2015120171A1 (en) 2015-08-13
SG11201606322XA (en) 2016-08-30
US20160311894A1 (en) 2016-10-27
US20180179272A1 (en) 2018-06-28
JP6549132B2 (ja) 2019-07-24
BR112016017926A2 (pt) 2017-10-10
US20180196065A1 (en) 2018-07-12
AU2015214103A1 (en) 2016-07-21
RU2016135417A (ru) 2018-03-12
EP3102951A1 (en) 2016-12-14
US9862762B2 (en) 2018-01-09

Similar Documents

Publication Publication Date Title
SG10201806729VA (en) Novel assay to detect human periostin
ZA202000935B (en) Methods and materials for assessing and treating cancer
PH12019501146A1 (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
MX2025004620A (es) Anticuerpos anti-lag3 radiomarcados para la obtencion de imagenes mediante inmuno-pet
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
MX336109B (es) Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
MX2020002243A (es) Anticuerpos utiles en diagnosis de cancer.
WO2015042326A3 (en) Methods for detection and treatment of neurodegenerative diseases
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
EP4184221A3 (en) P/s wave measurement and compensation
EP2937421A3 (en) Biomarker for predicting effect of an anti-C-met antibody
IL272484A (en) Systems and methods for improving disease diagnosis using measured test substances
MX2016010499A (es) Sistemas y métodos para identificar subtipos del receptor de progesterona.
MX384485B (es) Deteccion temprana de preeclampsia.
MX2016007148A (es) Metodos de ensayo de beta-glucano.
MX2021003484A (es) Metodos para detectar efecto(s) hook asociado(s) con analito(s) de interes durante o que resulta(n) de la realizacion de ensayo(s) de diagnostico.
EP3640643A3 (en) Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
SG10201901836PA (en) Test strip assembly
MX2017008748A (es) Ensayo para detectar dipeptidil peptidasa iv (dpp-4) humana.
MY187731A (en) In vivo induced toxoplasma gondii protein for application in diagnosis, vaccine and therapy
WO2017053703A3 (en) Composition and methods for assessing sensitivity and specificity of antibody detection reagents
TH1901003225A (th) แอนติ-pd-l1 แอนติบอดีซึ่งติดฉลากกัมมันต์สำหรับทำให้เกิดภาพอิมมูโน-pet
EA201401218A2 (ru) Способ нозологической экспресс-диагностики